ADVM · As filed with the SEC

Adverum Biotechnologies balance sheet, by fiscal year

The statement as Adverum Biotechnologies presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

CONSOLIDATED BALANCE SHEETS · USD thousands, except per-share amounts; shares in thousands

USD thousands, except per-share amounts; shares in thousands	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021
Assets
Current assets:
Cash and cash equivalents	60,652	75,000	68,431	34,195
Short-term investments	65,039	21,526	117,158	270,993
Lease incentive receivable	—	—	0	5,709
Prepaid expenses and other current assets	5,609	6,247	5,006	6,248
Total current assets	131,300	102,773	190,595	317,145
Operating lease right-of-use assets	33,611	52,266	78,934	86,000
Property and equipment, net	11,607	14,764	34,927	33,060
Restricted cash	1,976	1,976	2,503	2,503
Deferred rent receivable	—	—	0	769
Deposit and other long-term assets	1,347	1,231	1,413	250
Total assets	179,841	173,010	308,372	439,727
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	1,610	1,921	2,238	1,387
Accrued expenses and other current liabilities	15,620	12,584	16,767	18,047
Lease liability, current portion	5,668	10,409	13,241	1,886
Total current liabilities	22,898	24,914	32,246	21,320
Long-term liabilities:
Lease liability, net of current portion	86,037	64,627	93,561	101,108
Other non-current liabilities	192	0	1,047	1,114
Total liabilities	109,127	89,541	126,854	123,542
Stockholders’ equity:
Preferred stock, $0.0001 par value, 5,000 shares authorized; no shares issued and outstanding	0	0	0	0
Common stock, $0.0001 par value, 300,000 shares authorized at December 31, 2024: 20,848 and 10,143 shares issued and outstanding at December 31, 2024 and 2023, respectively	2	10	10	10
Additional paid-in capital	1,138,070	1,003,709	985,651	964,965
Accumulated other comprehensive loss	(407)	(473)	(1,531)	(714)
Accumulated deficit	(1,066,951)	(919,777)	(802,612)	(648,076)
Total stockholders’ equity	70,714	83,469	181,518	316,185
Total liabilities and stockholders’ equity	179,841	173,010	308,372	439,727
Common stock, shares issued (in shares)	20,848	—	—	—
Common stock, shares outstanding (in shares)	20,848	—	—	—
Common stock, shares authorized (in shares)	300,000	—	—	—
Common stock, par value (in USD per share)	0.00	—	—	—

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.